Literature DB >> 24958823

Irinotecan pharmacogenetics: a finished puzzle?

Mitch A Phelps1, Alex Sparreboom2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24958823     DOI： 10.1200/JCO.2014.56.3387

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

Review 1.  Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer.

Authors:  Fnu Asad Ur Rahman; Saeed Ali; Muhammad Wasif Saif
Journal:  Therap Adv Gastroenterol       Date:  2017-04-26       Impact factor: 4.409

2.  Different schedules of irinotecan administration: A meta-analysis.

Authors:  Yi Shao; Hui Lv; Dian-Sheng Zhong
Journal:  Mol Clin Oncol       Date:  2016-06-03

3.  ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Authors:  M Li; E L Seiser; R M Baldwin; J Ramirez; M J Ratain; F Innocenti; D L Kroetz
Journal:  Pharmacogenomics J       Date:  2016-11-15       Impact factor: 3.550

Review 4.  Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.

Authors:  J M Campbell; M D Stephenson; E Bateman; M D J Peters; D M Keefe; J M Bowen
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

Review 5.  Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

Authors:  Ken-ichi Fujita; Yutaro Kubota; Hiroo Ishida; Yasutsuna Sasaki
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

6.  Puerarin increases the chemosensitivity of hepatocellular carcinoma cells.

Authors:  Zhen Wu; Jing Wu; Ping Fang; Shifeng Kan
Journal:  Oncol Lett       Date:  2017-07-05       Impact factor: 2.967

7.  Treatment mechanism of matrine in combination with irinotecan for colon cancer.

Authors:  Ling Duan; Leijiao Deng; Dabin Wang; Shoucheng Ma; Chunmei Li; Da Zhao
Journal:  Oncol Lett       Date:  2017-06-19       Impact factor: 2.967

8.  Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28.

Authors:  Chuan Tian; Haifeng Ying; Rongyuan Zhuang; Xiaowei Zhang; Hongmin Lu; Hui Wang; Shuowen Wang; Qi Li; Chungang Wang; Xun Cai
Journal:  Cancer Manag Res       Date:  2018-11-22       Impact factor: 3.989
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.